Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak

Affiliations

• ¹ Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland; Faculty of Medicine, University of Geneva, Switzerland. Electronic address: silvia.stringhini@hcuge.ch.
• ² Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.
• ³ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
• ⁴ Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland; Faculty of Medicine, University of Geneva, Switzerland.
• ⁵ Faculty of Medicine, University of Geneva, Switzerland.
• ⁶ School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
• ⁷ Infection Control Program and WHO Collaborating Centre on Patient Safety, Geneva University Hospitals, Geneva, Switzerland; Faculty of Medicine, University of Geneva, Switzerland.
• ⁸ Division of General Pediatrics, Geneva University Hospitals, Geneva, Switzerland; Faculty of Medicine, University of Geneva, Switzerland.
• ⁹ Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Geneva, Switzerland; Faculty of Medicine, University of Geneva, Switzerland.
• ¹⁰ Faculty of Medicine, University of Geneva, Switzerland; Division of Internal Medicine, Hôpital de la Tour, Geneva, Switzerland.
• ¹¹ Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland; Faculty of Medicine, University of Geneva, Switzerland.
• ¹² Geneva Center for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland; Faculty of Medicine, University of Geneva, Switzerland.
• ¹³ Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.